NasdaqGM:KALVBiotechs
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next
KalVista Pharmaceuticals recently reported new interim results from its KONFIDENT-KID trial, showing that EKTERLY (sebetralstat) oral disintegrating tablets treated 172 hereditary angioedema attacks in 33 children aged 2–11 with rapid symptom relief and no serious or treatment-related adverse events.
The data highlight how an easy-to-administer oral option could address a major gap in pediatric hereditary angioedema care, where current on-demand treatment for young patients in the US is...